

Hematology and Oncology Publications

1. Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, **Kim YM**, Lomenick B, Okemoto K, Muschen M, Landaw E, Mazitschek R, Bradner JE, Sakamoto KM. Leuk Lymphoma 2011;52(8):1544-1555.
2. Andrade J, Ge S, Symbatyan G, Rosol MS, **Olch AJ**, Crooks GM. Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantation. Biol Blood Marrow Transplant 2011;17(5):608-619.
3. Ara T, **Declerck YA**. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010;46(7):1223-1231.
4. Arkader A, Phillips AL, **Olch A**, **Wong K**. A case of spontaneous hip dislocation that occurred during radiation therapy. J Pediatr Orthop B 2011.
5. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, **Seeger RC**, Matthay KK; Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363(14):1313-1323.
6. Beaty O 3rd, Berg S, Blaney S, **Malogolowkin M**, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2010;55(3):440-445.
7. **Berdoukas V**, Carson S, Nord A, Dongelyan A, Gavin S, **Hofstra TC**, Wood JC, **Coates T**. Combining two orally active iron chelators for thalassemia. Ann Hematol 2010;89(11):1177-1178.
8. **Berdoukas V**, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol 2011;4(1):17-26.
9. **Berdoukas V**, Wood J. In search of the optimal iron chelation therapy for patients with thalassemia major. Haematologica 2011;96(1):5-8.
10. Bergfeld SA, **DeClerck YA**. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010;29(2):249-261.
11. Blavier L, Lazaryev A, Shi XH, Dorey FJ, Shackelford GM, **DeClerck YA**. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther 2010;10(2):198-208.

12. Blüml S, Panigrahy A, Laskov M, **Dhall G**, Krieger MD, Nelson MD, **Finlay JL**, Gilles FH. Elevated citrate in pediatric astrocytomas with malignant progression. *Neuro Oncol* 2011;13(10):1107-1117.
13. Bonate PL, Cunningham CC, **Gaynon P**, Jeha S, Kadota R, Lam GN, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. *Cancer Chemother Pharmacol* 2011;67(4):875-890.
14. Bunin GR, Felice MA, Davidson W, Friedman DL, Shields CL, Maidment A, O'Shea M, Nichols KE, Leahey A, Dunkel IJ, **Jubran R**, Rodriguez-Galindo C, Schmidt ML, Weinstein JL, Goldman S, Abramson DH, Wilson MW, Gallie BL, Chan HS, Shapiro M, Cnaan A, Ganguly A, Meadows AT. Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutation. *Int J Cancer* 2011;128(10):2393-2404.
15. Chen HJ, Panigrahy A, **Dhall G**, **Finlay JL**, Nelson MD and Bluml S. Apparent diffusion and fractional anisotropy of diffuse intrinsic brain stem gliomas. *AJNR Am J Neuroradiol* 2010;31(10):1879-1885.
16. Chinn LW, Tang M, Kessing BD, Lautenberger JA, Troyer JL, Malasky MJ, McIntosh C, Kirk GD, Wolinsky SM, Buchbinder SP, **Gomperts ED**, Goedert JJ, O'Brien SJ. Genetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection. *J Infect Dis* 2010;202(12):1836-1845.
17. Chouliaras G, **Berdoukas V**, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. *J Magn Reson Imaging* 2011;34(1):56-59.
18. **Coates TD**. Is it time to SWITCH to composite primary endpoints? *Pediatr Blood Cancer* 2011.
19. **Coates TD**. So what if blood is thicker than water? *Blood* 2011;117(3):745-746.
21. Cooper A, van Doorninck J, Ji L, Russell D, Ladanyi M, Shimada H, Krailo M, Womer RB, Hsu JH, Thomas D, Triche TJ, **Sposto R**, Lawlor ER. Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group. *Clin Cancer Res* 2011;17(1):56-66.
22. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie SD, Parker R, Garvin J, **Finlay J**. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. *Pediatr Blood Cancer* 2010;54(3):377-383.

23. **Dhall G**, Khatua S, **Finlay JL**. Pineal region tumors in children. *Curr Opin Neurol* 2010;23(6):576-582.
24. **Dhall G**, Traverso M, **Finlay JL**, Shane L, Gonzalez-Gomez I, **Jubran R**. The role of chemotherapy in pediatric clival chordomas. *J Neurooncol* 2011;103(3):657-662.
25. Dibirdik I, Yiv, S., Qazi, S., **Uckun, FM**. In vivo anti-cancer activity of a liposomal nanoparticle construct of multifunctional tyrosine kinase inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. *J Nanomedicine Nanotechnology* 2010;1(1):001-004.
26. Dunkel IJ, Chan HS, **Jubran R**, Chantada GL, Goldman S, Chintagumpala M, Khakoo Y, Abramson DH. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. *Pediatr Blood Cancer* 2010;55(1):149-152.
27. Dunkel IJ, **Jubran RF**, Gururnagan S, Chantada GL, **Finlay JL**, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidan MM, Abramson DH. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. *Pediatr Blood Cancer* 2010;54(3):384-387.
28. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, **Kim YM**, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, **Heisterkamp N**, Graeber TG, Wu H, Ye BH, Melnick A, **Müschen M**. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. *Nature* 2011;473(7347):384-388.
29. Fang C, Wang Y, Vu N, Lin WY, Rubbi L, Hsieh YT, Muschen M, **Kim YM**, Chatziioannou A, Tseng HR, Graeber TG. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. *Cancer Res* 2010;70(21):8299-8308.
30. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, **Berdoukas V**. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. *Br J Haematol* 2010;148(3):466-475.
31. Fei F, Kweon SM, Haataja L, De Sepulveda P, **Groffen J**, **Heisterkamp N**. The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation Inhibitor alpha with the small GTPase Rac. *BMC Biochem* 2010;11:48.
32. Fei F, Stoddart S, **Groffen J**, **Heisterkamp N**. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. *Mol Cancer Ther* 2010;9(5):1318-1327.
33. Fei F, Stoddart S, **Müschen M**, **Kim YM**, **Groffen J**, **Heisterkamp N**. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. *Leukemia* 2010;24(4):813-820.

34. Ferrario A, **Gomer CJ**. Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor. *Methods Mol Biol* 2010;635:121-132.
35. Ferrario A, Lim S, Xu F, Luna M, Gaffney KJ, Petasis NA, Schönthal AH, **Gomer CJ**. Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. *Cancer Lett* 2011;304(1):33-40.
36. Forbes TJ, Hijazi ZM, **Young G**, Ringewald JM, Aquino PM, Vincent RN, Qureshi AM, Rome JJ, Rhodes JF Jr, Jones TK, Moskowitz WB, Holzer RJ, Zamora R. Pediatric catheterization laboratory anticoagulation with bivalirudin. *Catheter Cardiovasc Interv* 2011.
37. **Freyer DR**. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. *J Clin Oncol* 2010;28(32):4810-4818.
38. **Freyer DR**, Devidas M, La M, Carroll WL, **Gaynon PS**, Hunger SP, Seibel NL. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. *Blood* 2011;117(11):3010-3015.
39. **Gaynon PS**, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. *Leukemia* 2010;24(2):285-297.
40. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, **Spoto R**, **Gaynon PS**, Loh ML. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. *Pediatr Blood Cancer* 2010;55(3):421-429.
41. Gruber TA, Chang MS, **Spoto R**, **Müschen M**. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. *Cancer Res* 2010;70(19):7411-7420.
42. Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, **Malogolowkin MH**, Meyers RL, Grant D, Grant RM. Critical review of controversial issues in the management of advanced pediatric liver tumors. *Pediatr Blood Cancer* 2010;56(7):1013-1018.
43. Hayes-Lattin B, Mathews-Bradshaw B, Siegel S. Adolescent and young adult oncology training for health professionals: a position statement. *J Clin Oncol* 2010;28(32):4858-4861.
44. Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA, Goedert JJ, Kirk GD, **Gomperts ED**, Buchbinder SP, Troyer

- JL, O'Brien SJ. Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. *PLoS One* 2010;5(9):e12862.
45. Hingorani P, Seidel K, Krailo M, **Mascarenhas L**, Meyers P, Marina N, Conrad EU, Hawkins DS. Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2011;57(6):939-942.
 46. Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, **Asgharzadeh S**, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. *Cell* 2010;142(2):218-229.
 47. Horton TM, **Sposto R**, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, **Gaynon PS**, Gore L, Jeha S, Maurer BJ, **Siegel SE**, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. *Pediatr Blood Cancer* 2010;54(7):872-878.
 48. Hu H, Du L, Nagabayashi G, **Seeger RC**, Gatti RA. ATM is down-regulated by N-Myc-regulated microRNA-421. *Proc Natl Acad Sci U S A* 2010;107(4):1506-1511.
 49. Huang JM, Sheard MA, Ji L, **Sposto R**, Keshelava N. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. *Mol Cancer Ther* 2010;9(12):3289-3301.
 50. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, Lee S, **Jong A**. Invasion of *Cryptococcus neoformans* into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). *J Biol Chem* 2011;286(40):34761-34769.
 51. Huang SH, Wu CH, Jiang S, Bahner I, Lossinsky AS, **Jong AY**. HIV-1 gp41 ectodomain enhances *Cryptococcus neoformans* binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. *Biochem J* 2011;438(3):457-466.
 52. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, **Young G**, Bidlingmaier C, Brandao L R, Ettingshausen C E, Gringeri A, Kenet G, Knofler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci P M, Nowak-Gottl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or

- recombinant factor VIII concentrates: a systematic review. *J Thromb Haemost* 2010;8(6):1256-1265.
53. Isono M, Suzuki T, Hosono K, Hayashi I, Sakagami H, Uematsu S, Akira S, **DeClerck YA**, Okamoto H, Majima M. Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. *Life Sci* 2011;88(15-16):693-700.
 54. Kelly KM, **Sposto R**, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. *Blood* 2011;117(9):2596-2603.
 55. Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Gunther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostasy K, Simioni P, Strater RD, **Young G**, Nowak-Gotti U. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. *Circulation* 2010;121(16):1838-1847.
 56. Khatua S, **Dhall G**, **O'Neil S**, **Jubran R**, Villablanca JG, **Marachelian A**, Nastia A, Lavey R, **Olch AJ**, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, **Sposto R**, **Finlay JL**. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. *Pediatr Blood Cancer* 2010;55(1):42-46.
 57. Khatua S, Phillips A, Fangusaro J, Bovan S, **Dhall G**, **Finlay JL**. Recurrent pure CNS germinoma with markedly elevated serum and cerebrospinal fluid human chorionic gonadotropin-beta (HCGbeta). *Pediatr Blood Cancer* 2011;56(5):863-864.
 58. [Kim YM](#), [Ma H](#), [Oehler VG](#), [Gang EJ](#), [Nguyen C](#), [Masiello D](#), [Liu H](#), [Zhao Y](#), [Radich J](#), [Kahn M](#). The gamma catenin/CBP complex maintains survivin transcription in beta-catenin deficient/depleted cancer cells. *Curr Cancer Drug Targets* 2011;11(2):213-225.
 59. **Ko RH**, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, **Sposto R**, **Gaynon PS**, Loh ML. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. *J Clin Oncol* 2010;28(4):648-654.

60. Konijnenberg MW, **Olch A**. Pediatric dosimetry for intrapleural lung injections of (32)P chromic phosphate. *Phys Med Biol* 2010;55(19):5735-5751.
61. Ladis V, Chouliaras G, **Berdoukas V**, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Kattamis A, Karagiorga-Lagana M. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. *Eur J Haematol* 2011;86(4):332-338.
62. Ladis V, Chouliaras G, **Berdoukas V**, Moraitis P, Zannikos K, Berdoussi E, Kattamis C. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. *Eur J Haematol* 2010;85(4):335-344.
63. Li A, Xing Y, Chan B, **Heisterkamp N**, **Groffen J**, Borok Z, Minoo P, Li C. Cell type-specific expression of adenomatous polyposis coli in lung development, injury, and repair. *Dev Dyn* 2010;239(8):2288-2297.
64. Long M, Cao H, **Jong A**. [Effect of HIV-1gp41 ectodomain on Cryptococcus neoformans-induced cytoskeletal changes in human brain microvascular endothelial cells]. *Nan Fang Yi Ke Da Xue Xue Bao* 2011;31(3):478-481.
65. Luna M, Ferrario A, Wong S, **Gomer CJ**. Identification of MAP kinase pathways involved in COX-2 expression following photofrin photodynamic therapy. *Methods Mol Biol* 2010;635:47-63.
66. Madabushi R, Cox DS, Hossain M, Boyle DA, Patel BR, **Young G**, Choi YM, Gobburu JV. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. *J Clin Pharmacol* 2011;51(1):19-28.
67. Mahadeo KM, **Dhall G**, Ettinger LJ, Kurer CC. Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction. *J Pediatr Hematol Oncol* 2010;32(2):134-136.
68. Mahadeo KM, **Dhall G**, Panigrahy A, Lastra C, Ettinger LJ. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. *Pediatr Hematol Oncol* 2010;27(1):46-52.
69. **Malogolowkin MH**, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, Finegold MJ. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. *J Clin Oncol* 2011;29(24):3301-3306.

70. **Mascarenhas L**, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2011;28(30):4658-4663.
71. Massimino M, Cohen KJ, **Finlay JL**. Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? *Pediatr Blood Cancer* 2010;54(4):641-643.
72. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, **Gaynon PS**. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood* 2011;118(2):243-251.
73. Messinger Y, **Gaynon P**, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, **Spoto R**, van der Giessen J, Eckroth E, Bostrom BC. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. *Pediatr Blood Cancer* 2010;55(2):254-259.
74. Moreno L, Pollack IF, Duffner PK, Geyer RJ, Grill J, Massimino M, **Finlay JL**, Zacharoulis S. Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. *J Pediatr Hematol Oncol* 2010;32(6):515-518.
75. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, **Muschen M**, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. *Clin Cancer Res* 2011;17(10):3219-3232.
76. Noetzli LJ, Carson S, **Coates TD**, Wood JC Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. *Eur J Haematol* 2011;86(2):176-177.
77. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, **Asgharzadeh S**, **Seeger R**, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B,

- Fischer M. Prognostic impact of gene expression-based classification for neuroblastoma. *J Clin Oncol* 2010;28(21):3506-3515.
78. Oh D, Han S, Seo J, Lee J-R, Choi J, **Groffen J**, Kim K, Cho YS, Choi H-S, Shin H, Woo J, Won H, Park SK, Kim S-Y, Jo J, Whitcomb DJ, Cho K, Kim H, Bae YC, **Heisterkamp N**, Choi S-Y, Kim, E. Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins. *J Neurosci* 2010;30(42):14134-14144.
79. **Olch AJ**, Whitaker ML. Validation of a treatment plan-based calibration method for 2D detectors used for treatment delivery quality assurance. *Med Phys* 2010;37(8):4485-4494.
80. **O'Neil S**, Azoff J, **Dhall G**, Khatua S, Borchert M, **Spoto R**, **Finlay JL**. Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation. *Pediatr Blood Cancer* 2011;57(4):669-673.
81. Orgel E, Jain S, Ji L, Pollick L, Si S, **Finlay J**, **Freyer DR**. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. *Pediatr Blood Cancer* 2011.
82. Parameswaran R, **Müschen M**, **Kim YM**, **Groffen J**, **Heisterkamp N**. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. *Cancer Res* 2010;70(11):4346-4356.
83. Parameswaran R, Yu M, Lim M, **Groffen J**, **Heisterkamp N**. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. *Leukemia* 2011;25(8):1314-1323.
84. Parekh C, **Hofstra T**, Church JA, **Coates TD**. Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. *Pediatr Blood Cancer* 2011;56(3):460-462.
85. Parekh C, **Jubran R**, **Erdreich-Epstein A**, Panigrahy A, Bluml S, **Finlay J**, **Dhall G**. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. *J Neurooncol* 2011;103(3):673-680.
86. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, **Heisterkamp N**, Pelus L, Keerthivasan G, Crispino J, Kahn M, **Müschen M**, **Kim YM**. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. *Blood* 2011;118(8):2191-2199.
87. Patel, S, Mullins, W, **O'Neil, S**, Wilson, K. Neuropsychological differences between survivors of supratentorial and infratentorial brain tumours. *J Intellect Disabil Res* 2011;55(1):30-40.

88. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforova YE, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Giolles FH, Yates AJ, Zhou T, Cohen KJ, **Finlay JL**, Jakacki RI . Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2010;55(6):1066-1071.
89. Qazi S, **Uckun FM**. Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. *Br J Haematol* 2010;149(6):865-873.
90. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, **Müschen M**, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. *Sci Signal* 2011;4(166):ra18.
91. Russell HV, Groshen SG, Ara T, **DeClerck YA**, Hawkins R, Jackson HA, Daldrup-Link HE, **Marachelian A**, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. *Pediatr Blood Cancer* 2011;57(2):275-282.
92. Rutkowski S, Cohen B, **Finlay J**, Ridola V, Valteau-Couanet, Hara J, Garre M-L, Grill J. Medulloblastoma in young children. *Pediatr Blood Cancer* 2010;54(4):635-637.
93. Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison DW, Garre ML, Biassoni V, Grundy RG, **Finlay JL**, **Dhall G**, Raquin MA, Grill J. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. *J Clin Oncol* 2010;28(33):4961-4968.
94. Sands SA, Oberg JA, Gardner SL, Whiteley JA, Glade-Bender JL, **Finlay JL**. Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: an analysis of the Head Start II survivors. *Pediatr Blood Cancer* 2010;54(3):429-436.
95. Sands SA, Pasichow KP, Weiss R, Garvin J, Gardner S, Dunkel IJ, **Finlay JL**. Quality of life and behavioral follow-up study of Head Start I pediatric brain tumor survivors. *J Neurooncol* 2011;101(2):287-295.
96. Sangkatumvong S, Khoo MCK, Kato R, Detterich JA, Bush A, Keens TG, Meiselman HJ, Wood JC, **Coates TD**. Peripheral vasoconstriction and

- abnormal parasympathetic response to sighs and transient hypoxia in sickle cell disease. *Am J Respir Crit Care Med* 2011;184(4):474-481.
97. Serowka K, Chiu Y, Gonzalez I, Gilles FR, McComb G, Krieger M, **Dhall G**, Britt B, Ji L, **Sposto R** and **Finlay J**. Central nervous system (CNS) tumors in the first six months of life: the Children's Hospital Los Angeles experience, 1979-2005. *Pediatr Hematol Oncol* 2010;27(2):90-102.
 98. Si SJ, Khatua S, **Dhall G**, Nelson MD, Gonzalez-Gomez I, **Finlay JL**. Regression of primary central nervous system germinoma after dexamethasone administration: a case report. *Pediatr Hematol Oncol* 2010;27(3):237-243.
 99. Song HR, Gonzalez-Gomez I, Suh GS, Commins DL, **Sposto R**, Gilles FH, Deneen B, **Erdreich-Epstein A**. Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. *Neuro Oncol* 2010;12(2):122-132.
 100. Souweidane MM, Weiner H, Krieger M, **Finlay JL**. Surgical management of primary central nervous system germ cell tumors: proceedings from the Second International Symposium on Central Nervous System Germ Cell Tumors. *J Neurosurg Pediatr* 2010;6(2):125-130.
 101. Splinter A, Min S, Balkian A, **Quinn JJ**. Pediatric anaplastic large cell lymphoma presenting as generalized lymphadenopathy. *Oncology (Williston Park)* 2010;24(10):954-956, 958.
 102. **Sposto R**. Commentary on paper, 'cancer survival analysis'. *Surg Oncol* 2010;19(2):59-60; discussion 61.
 103. **Sposto R**, Groshen S. A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. *Contemp Clin Trials* 2011;32(5):694-703.
 104. Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, **Gaynon PS**. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. *Blood* 2010;115(14):2740-2748.
 105. Stuber ML, **Meeske KA**, Krull KR, Leisenring W, Stratton K, Kazak AE, Huber M, Zebrack B, Uijtdehaage SH, Mertens AC, Robison LL, Zeltzer LK. Prevalence and predictors of posttraumatic stress disorder in adult survivors of childhood cancer. *Pediatrics* 2010;125(5):e1124-1134.
 106. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon, N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, **Finlay J**, Malkin D. TP53 alterations determine clinical

- subgroups and survival of patients with choroid plexus tumors. *J Clin Oncol* 2010;28(12):1995-2001.
107. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, Kwiatkowski J, Thompson AA, Porter J, **Coates T**, Giardina PJ, Olivieri N, Yamashita R, Neufeld EJ. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. *Am J Hematol* 2011;86(5):433-436.
 108. Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, Johnson RC, Sezgin E, Kessing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An P, Winkler CA, Limou S, Le Clerc S, Delaneau O, Zagury JF, Schuitemaker H, van Manen D, Bream JH, **Gomperts ED**, Buchbinder S, Goedert JJ, Kirk GD, O'Brien SJ. Genome-wide association study implicates PARD3B-based AIDS restriction. *J Infect Dis* 2011;203(10):1491-1502.
 109. **Uckun FM**, Dibirdik I. Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor. *Nutr Cancer* 2010;62(7):968-972.
 110. **Uckun FM**, Dibirdik I, Qazi S. Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). *Radiat Res* 2010;174(4):526-531.
 111. **Uckun FM**, Dibirdik I, Qazi S. Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase. *Arzneimittelforschung* 2010;60(4):218-225.
 112. **Uckun FM**, Dibirdik I, Qazi S, Yiv S. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. *Arzneimittelforschung* 2010;60(4):210-217.
 113. **Uckun FM**, Ek RO, Jan ST, Chen CL, Qazi S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. *Br J Haematol* 2010;149(4):508-517.
 114. **Uckun FM**, Goodman P, Ma H, Dibirdik I, Qazi S. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia. *Proc Natl Acad Sci U S A* 2010;107(39):16852-16857.
 115. **Uckun FM**, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress. *Br J Haematol* 2010;148(5):714-725.
 116. **Uckun FM**, Pitt J, Qazi S. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. *Expert Rev Anticancer Ther* 2011;11(1):37-48.

117. **Uckun FM**, Qazi S. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity. *Expert Opin Ther Pat* 2010;20(11):1457-1470.
118. **Uckun FM**, Qazi S. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas. *Expert Rev Anticancer Ther* 2010;10(9):1407-1418.
119. **Uckun FM**, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. *Proc Natl Acad Sci U S A* 2010;107(7):2902-2907.
120. **Uckun FM**, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, Janda KD. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. *Br J Haematol* 2011;153(6):741-752.
121. **Uckun FM**, Sun L, Qazi S, Ma H, Ozer Z. Recombinant human CD19-ligand protein as a potent anti-leukaemic agent. *Br J Haematol* 2011;153(1):15-23.
122. Venkatramani R, **Dhall G**, Patel M, Grimm J, Hawkins C, McComb G, Krieger M, **Wong K**, **O'Neil S**, **Finlay JL**. Supratentorial ependymoma in children: To observe or to treat following gross total resection? *Pediatr Blood Cancer* 2011.
123. Venkatramani R, Ma NS, Pitukcheewanont P, **Malogolowkin MH**, **Mascarenhas L**. Gorham's disease and diffuse lymphangiomatosis in children and adolescents. *Pediatr Blood Cancer* 2011;56(4):667-670.
124. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, **Coates T**. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. *Br J Haematol* 2011;154(3):387-397.
125. **Villablanca JG**, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. *Clin Cancer Res* 2011;17(21):6858-6866.
126. Villani A, Tabori U, Schiffman J, Shlien A, Druker H, Novokmet A, **Finlay J**, Malkin D. Biochemical and imaging surveillance in germline TP53

- mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncol* 2011;12(6):559-567.
127. Wang LI, Lin YS, Liu KH, **Jong AY**, Shen WC. Cryptococcus neoformans mediator protein Ssn8 negatively regulates diverse physiological processes and is required for virulence. *PLoS One* 2011;6(4):e19162.
128. Warden M, Pique-Regi R, Ortega A, **Asgharzadeh S**. Bioinformatics for copy number variation data. *Methods Mol Biol* 2011;719:235-249.
129. Wolfson J, **Ruccione K**, Reaman GH. Health care reform 2010: expected favorable impact on childhood cancer patients and survivors. *Cancer J* 2010;16(6):554-562.
130. Wolfson JA, Schragger SM, **Coates TD**, Kipke MD. Sickle-cell disease in California: a population-based description of emergency department utilization. *Pediatr Blood Cancer* 2011;56(3):413-419.
131. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, **Coates TD**. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. *Am J Hematol* 2010;85(10):818-819.
132. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, **Coates TD**. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. *Blood* 2010;116(4):537-543.
133. Wood J, Mo A, Gera A, Koh M, **Coates T**, Gilsanz V. Quantitative computed tomography assessment of transfusional iron overload. *Br J Haematol* 2011;153(6):780-785.
134. Wood JC, Noetzi L, Hyderi A, Joukar M, **Coates T**, Mittelman S. Predicting pituitary iron and endocrine dysfunction. *Ann N Y Acad Sci* 2010;1202:123-128.
135. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, **Coates TD**. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. *Haematologica* 2011;96(7):1055-1058.
136. Wu CC, **Asgharzadeh S**, Triche TJ, D'Argenio DZ. Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. *Bioinformatics* 2010;26(6):807-813.
137. Xu J, Millard M, Ren X, Cox OT, **Erdreich-Epstein A**. c-Abl mediates endothelial apoptosis induced by inhibition of integrins α v β 3 and α v β 5 and by disruption of actin. *Blood* 2010;115(13):2709-2718.
138. Yi SJ, **Groffen J**, **Heisterkamp N**. Bcr is a substrate for Transglutaminase 2 cross-linking activity. *BMC Biochem* 2011;12:8.

139. **Young G.** Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population. *Blood Coagul Fibrinolysis* 2010;21 Suppl 1:S7-10.
140. **Young G.** New anticoagulants in children: a review of recent studies and a look to the future. *Thromb Res* 2011;127(2):70-74.
141. **Young G,** Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. *Pediatr Blood Cancer* 2011;57(6):1049-1054.
142. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, **Seeger R,** Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N Engl J Med* 2010;363(14):1324-1334.
143. Yu M, Jiang E, Parameswaran R, Stoddart S, Fei F, **Muschen M,** Park E, Hsieh Y-T, Martinelli G, Hofmann W-K, Yang AS, **Groffen J, Heisterkamp N, Kim Y-M.** AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo. *Blood Cancer Journal* 2011;1(e14).
144. Yun JP, Behan JW, **Heisterkamp N,** Butturini A, Klemm L, Ji L, **Groffen J, Muschen M,** Mittelman SD. Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. *Cancer Prev Res (Phila)* 2010;3(10):1259-1264.
145. Zebrack B, Mathews-Bradshaw B, **Siegel S.** Quality cancer care for adolescents and young adults: a position statement. *J Clin Oncol* 2010;28(32):4862-4867.
146. Zebrack BJ, Stuber ML, **Meeske KA,** Phipps S, Krull KR, Liu Q, Yasui Y, Parry C, Hamilton R, Robison LL, Zeltzer LK. Perceived positive impact of cancer among long-term survivors of childhood cancer: a report from the childhood cancer survivor study. *Psychooncology* 2011.